|
| Press Releases |
|
 |
|
| Friday, August 12, 2022 |
|
|
云康集团公佈上巿後首個中期業績 純利上升50%至人民幣2.34億元 |
| 領先的中國醫學運營服務應供商云康集团有限公司（「云康」或「集團」；股份代號：2325）公布截至2022年6月30日止（「報告期」）上巿後首個中期業績。 more info >> |
|
|
Yunkang Group Announces First Interim Results Since Listing, Net Profit Rises 50% to RMB234 Million |
| Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its first interim results for the six months ended 30 June 2022 (the "Reporting Period") since its listing. more info >> |
|
| Saturday, May 21, 2022 |
|
|
云康集团 (02325.HK) 冀为中国医疗系统创新发展 |
新股云康集团(2325)一直致力于深化在医疗领域方面的技术，与不同的机构共同合作，推动科研成果产业化；共同培训高素质人才；改革医疗措施、优化医疗系统方面的效率，提高基层医院的诊断能力及容量，运用长期以来的科研技术带来中国医疗系统的突破。
more info >> |
|
|
雲康集團 (02325.HK) 冀為中國醫療系統創新發展 |
| 新股雲康集團(2325)一直致力於深化在醫療領域方面的技術，與不同的機構共同合作，推動科研成果產業化；共同培訓高素質人才；改革醫療措施、優化醫療系統方面的效率，提高基層醫院的診斷能力及容量，運用長期以來的科研技術帶來中國醫療系統的突破。 more info >> |
|
| Wednesday, May 18, 2022 |
|
|
云康集团成功登陆香港交易所主板 |
中国医学运营服务提供商 ── 云康集团有限公司 (「云康集团」或「公司」，股份代号：2325 )，正式登陆香港交易所主板市场，股份代号为2325，每手买卖单位为500股股份。
more info >> |
|
|
雲康集團成功登陸香港交易所主板 |
| 中國醫學運營服務提供商 ── 雲康集團有限公司 (「雲康集團」或「公司」，股份代號：2325 )，正式登陸香港交易所主板市場，股份代號為2325，每手買賣單位為500股股份。 more info >> |
|
|
Yunkang Group Limited Successfully Listed on the Main Board of HKEX |
| A medical operation services provider in China - Yunkang Group Limited ("Yunkang Group" or the "Company", stock code: 2325.HK, together with its subsidiaries, collectively as the "Group"), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange") today, under the stock code of 2325 and in board lot of 500 shares each. more info >> |
|
| Saturday, May 7, 2022 |
|
|
新股消息：市传云康集团（02325）国际配售足额认购 |
| 中国医学营运服务商云康集团（02325）于周四（5日）开始招股，据市场消息，国际配售认购反应理想，已获足额认购，吸引了有名的长线基金进来，预期认购仍会持续升温。 more info >> |
|
|
新股消息：市傳雲康集團（02325）國際配售足額認購 |
| 中國醫學營運服務商雲康集團（02325）於周四（5日）開始招股，據市場消息，國際配售認購反應理想，已獲足額認購，吸引了有名的長線基金進來，預期認購仍會持續升溫。 more info >> |
|
| Thursday, May 5, 2022 |
|
|
云康集团有限公司宣布于香港交易所主板上市计划 |
| 中国医学运营服务提供商 ── 云康集团有限公司 (「云康集团」或「公司」，股份代号：2325 )，今天宣布于香港交易所有限公司(「香港交易所」) 主板上市计划。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Kangji Medical Receives Privatisation Proposal from a Consortium Led by Kangji Medical's Chairman, Zhong Ming, TPG and QIA to Advance Long-Term Strategic Vision
Aug 13, 2025 23:21 HKT/SGT
|
|
|
GEON Performance Solutions Achieves Great Place to Work Recognition Globally Second Year in a Row
Aug 13, 2025 23:18 HKT/SGT
|
|
|
AI Inference vs. AI Training: What Are the Differences?
Aug 13, 2025 23:03 HKT/SGT
|
|
|
Shoucheng Joins World Humanoid Robot Games - 88 Spectators Invited
Aug 13, 2025 22:33 HKT/SGT
|
|
|
MMG Announces 2025 Interim Results, Profit, Earnings and Cash up on Strong Copper Growth
Aug 13, 2025 22:31 HKT/SGT
|
|
|
Formerra Becomes North American Distributor for Syensqo PVDF
Aug 13, 2025 21:32 HKT/SGT
|
|
|
China Lilang Announces 2025 Interim Results
Aug 13, 2025 21:30 HKT/SGT
|
|
|
NMPA已受理亿胜生物关于EB12-20145P（HLX04-O）用于治疗湿性年龄相关性黄斑变性的生物制品许可申请
Aug 13, 2025 21:25 HKT/SGT
|
|
|
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
Aug 13, 2025 21:24: JST
|
|
|
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
Aug 13, 2025 20:24 HKT/SGT
|
|
|
NMPA已受理億勝生物關於EB12-20145P（HLX04-O）用於治療濕性年齡相關性黃斑變性的生物製品許可申請
Aug 13, 2025 20:24 HKT/SGT
|
|
|
潼關黃金獲納入MSCI全球小型股指數 資本市場影響力進一步提升
Aug 13, 2025 19:19 HKT/SGT
|
|
|
AsiaMedic Reports 26% Revenue Growth to S$16.6 million in 1H2025, Led by Strong Diagnostic Imaging Performance
Aug 13, 2025 14:00 HKT/SGT
|
|
|
74th China (Linyi) International Hardware Expo to Open September 5-7, 2025 in Shandong
Aug 13, 2025 13:00: JST
|
|
|
74th China (Linyi) International Hardware Expo to Open September 5-7, 2025 in Shandong
Aug 13, 2025 12:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
